ALXO 8-K SEC Filing Analysis

Latest settled — T+20d

ALXO ▲ +18.86% at T+20d

NEUTRAL call ✓ call won +18.86% · α vs SPY +11.13% · entry $1.75 → $2.08

Next anchor: T+60d in 23d

Last close $1.58 (close Jun 12) · -9.71% from $1.75 entry

Entry anchored
Apr 10, 03:59 PM ET
via Databento tick

T+1d

-7.71%

call -7.71% · α -8.92%

$1.62

settled 2mo ago

T+5d

0.00%

call 0.00% · α -3.30%

$1.75

settled 8w ago

T+20d

+18.86%

call +18.86% · α +11.13%

$2.08

settled 5w ago

T+60d

—

call — · α —

—

in 23d

Price Chart

Loading chart...

Executive Summary

ALX Oncology appointed Jeff Knight as Chief Development and Operating Officer on April 13, 2026, with an annual base salary of $565,000 and a stock option grant to purchase 800,000 shares. The announcement was made via a press release furnished under Item 7.01.

Actionable Insight

Monitor for potential pipeline acceleration given Knight's oncology development background, but no immediate financial impact expected from this personnel change.

Key Facts

Jeff Knight appointed as Chief Development and Operating Officer effective April 13, 2026
Annual base salary set at $565,000 with eligibility for a 40% target cash bonus
Received stock option to purchase 800,000 shares, vesting 25% on first anniversary and monthly thereafter
Entered into standard change of control and severance agreement
Announcement made through press release under Item 7.01

Financial Impact

Compensation package includes $565,000 annual base salary and equity grant valued at approximately $4.5 million based on current market price

operating expensesshare dilutionstock-based compensation

Risk Factors

Integration risk with existing management team
Failure to execute on upcoming clinical catalysts despite new leadership

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-152050
Document: alxo-ex99_1.htm	0001193125-26-152050
Document: 0001193125-26-152050-index-headers.html	0001193125-26-152050
Document: 0001193125-26-152050-index.html	0001193125-26-152050
Document: 0001193125-26-152050.txt	0001193125-26-152050

8 reports for ALXO

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ALXO — sortable, filterable
	Type				Now
Jun 12, 2026 3d ago	Institutional Cluster BEARISH ★ 5/10	$1.52 awaiting T+20	awaiting T+20	—	$1.58 (−3.95%)
May 8, 2026 5w ago	8-K NEUTRAL ★ 5/10	$2.08 $1.54	▼ −25.96%	▼ −25.98%	$1.58 (−24.04%)
May 8, 2026 5w ago	Press Release BEARISH ★ 6/10	$2.08 $1.54	▲ +25.96%	▲ +25.98%	$1.58 (+24.04%)
May 7, 2026 5w ago	Press Release NEUTRAL ★ 4/10	$1.87 $1.67	▼ −10.70%	▼ −13.83%	$1.58 (−15.51%)
Apr 13, 2026 8w ago	8-K NEUTRAL ★ 3/10	$1.75 $2.08	▲ +18.86%	▲ +11.13%	$1.58 (−9.71%)
Mar 19, 2026 12w ago	Insider Cluster NEUTRAL ★ 3/10	$2.19 $1.67	▼ −23.74%	▼ −31.37%	$1.58 (−27.85%)
Feb 28, 2026 15w ago	Institutional Cluster BULLISH ★ 7/10	$2.12 $1.91	▼ −9.91%	▼ −1.97%	$1.58 (−25.47%)
Feb 27, 2026 15w ago	Press Release MIXED ★ 6/10	$2.11 $2.04	▼ −3.32%	▲ +4.24%	$1.58 (−25.12%)

US Market Status

Market Closed — Opens in 4h 58m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access